世界の分子細胞遺伝学市場：技術別、用途別、製品別、エンドユーザー別、地域別動向 - 成長、動向、予測

当レポートでは、世界の分子細胞遺伝学市場について調査し、市場の概要と技術別、用途別、製品別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な推論

第5章 市場概要

• 現在の市場シナリオ
• ポーターズファイブフォース分析

第6章 市場動向

• 市場促進因子
• 市場阻害因子
• 機会
• 主な課題

第7章 市場セグメンテーション

• 技術別
  • in situハイブリッド化における蛍光
  • in situハイブリッド化
  • 比較ゲノムハイブリッド化
  • 免疫組織化学
  • 染色体分析
  • その他
• 用途別
  • 遺伝子疾患
  • 癌
  • 個別化医療
  • その他
• 製品別
  • 計器
  • 試薬
  • ソフトウェア・サービス
• エンドユーザー別
  • バイオ医薬品メーカー
  • 研究機関
  • 学術機関
• 地域別
  • 北米
  • 欧州
  • アジア太平洋地域
  • 中東・アフリカ
  • 南米

第8章 競合環境

• 合併・買収分析
• 協定、連携、提携
• 新製品上市

第9章 主要参入企業

• Abbott
• Agilent Technologies, Inc.
• Applied Spectral Imaging, Inc.
• Bio-Rad Laboratories, Inc.
• Cytognomix, Inc.
• F. Hoffmann-La Roche Ltd
• Illumina, Inc.
• PerkinElmer, Inc.
• Quest Diagnostics Incorporated
• Thermo Fisher Scientific

第10章 市場の将来

The molecular cytogenetics deals with all aspects of chromosome biology with a wide range of applications in disease diagnosis and chromosomal abnormalities. The growing prevalence of cancer and genetic disorders patients has a direct rising impact on the increased demand of the molecular cytogenetic market. According to the World Health Organization (WHO), cancer is the second most important cause of death and morbidity in Europe, with more than 3.7 million new cases and 1.9 million deaths each year, with tobacco and excessive alcohol consumption being the primary reasons. The genetic data accumulated each day are closely associated with the diagnosis and prognosis of neoplasm, thus widening the scope of cancer cytogenetics in various practices. Genetic diseases and their connections with brain disorders, such as Down syndrome, Edwards's syndrome, Patau syndrome, and Turner syndrome are among the few prominent diseases that have several applications in molecular cytogenetics. Thus, with the increasing prevalence of cancers and genetic diseases, the demand for molecular cytogenetics is expected to register significant rise in the forecast years.

Key Market Trends

Cancer Segment is Expected to Show Better Growth over the Forecast Period

Based on application, it is segmented into cancer, genetic disorders and other applications. Molecular cytogenetics has played an important role in rapid and precise characterization of cancer chromosome abnormalities. Oncology deals with the diagnosis and treatment of tumors and cancers. Cancer is one of the leading causes of morbidity and mortality. Among both sexes, lung, breast, and colorectal cancers are among the most common cancers in the world, with lung cancer alone contributing to more than 13% of the total cases diagnosed. Thus, with the increasing burden of cancer, the demand for diagnosis is increasing, resulting in the high growth of the studied market.

North America is Expected to Dominate the Molecular Cytogenetics Market

The molecular cytogenetics market dominate the North America region due to better healthcare infrastructure, effective government policies, huge base of multinational companies, and high awareness among people. Molecular cytogenetics tests are covered under the National Insurance Policy, in Medicare. The major focus has been on the Centers for Medicare and Medicaid Services. Furthermore, growing geriatric population, along with increasing demand for in-vitro diagnostics testing for the detection of various chronic diseases is expected to drive the market over the forecast period.

Competitive Landscape

The global players into the molecular cytogenetics market are Abbott Laboratories, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., F.Hoffmann-La Roche Ltd., Illumina, Inc., Oxford Gene Technology, PerkinElmer Inc, Quest Diagnostics and Thermo Fisher Scientific.

Reasons to Purchase this report:

• The market estimate (ME) sheet in Excel format
• Report customization as per the client's requirements
• 3 months of analyst support

Table of Contents

1 INTRODUCTION

• 1.1 Study Deliverables
• 1.2 Study Assumptions
• 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing Prevalence of Cancer and Genetic Disorders
  • 4.2.2 Increasing Focus on Targeted Therapies for Cancer Treatment
  • 4.2.3 Rise in Funding for Research and Clinical Diagnosis
• 4.3 Market Restraints
  • 4.3.1 High Cost of Treatment
  • 4.3.2 Lack of Awareness about the Emerging Diagnostic Technologies in Cytogenetics
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

• 5.1 By Products
  • 5.1.1 Instruments
  • 5.1.2 Kits & Reagents
  • 5.1.3 Software & Services
• 5.2 By Technique
  • 5.2.1 Fluorescence in Situ Hybridization
  • 5.2.2 Comparative Genomic Hybridization
  • 5.2.3 Karyotyping
  • 5.2.4 Other Techniques
• 5.3 By Application
  • 5.3.1 Cancer
  • 5.3.2 Genetic Disorders
  • 5.3.3 Other Applications
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle-East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle-East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Abbott Laboratories
  • 6.1.2 Agilent Technologies, Inc.
  • 6.1.3 Bio-Rad Laboratories, Inc.
  • 6.1.4 F.Hoffmann-La Roche Ltd.
  • 6.1.5 Illumina, Inc.
  • 6.1.6 Oxford Gene Technology
  • 6.1.7 PerkinElmer, Inc.
  • 6.1.8 Quest Diagnostics
  • 6.1.9 Thermo Fisher Scientific

7 MARKET OPPORTUNITIES AND FUTURE TRENDS